Real‐life experience of upadacitinib for the treatment of adult patients with moderate‐to‐severe atopic dermatitis – a case series

Journal of the European Academy of Dermatology and VenereologyVolume 36, Issue 10 p. e832-e833 Letter to the Editor Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis – a case series G. Feraru, Corresponding Author G. Feraru [email protected] orcid.org/0000-0003-4894-197X Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Division of Dermatology, Emek Medical Center, Afula, IsraelCorrespondence: G. Feraru. E-mail: [email protected]Search for more papers by this authorM.J. Nevet, M.J. Nevet Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Division of Dermatology, Rambam Health Care Campus, Haifa, IsraelSearch for more papers by this authorL. Samuelov, L. Samuelov orcid.org/0000-0001-5387-5490 Division of Dermatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, IsraelSearch for more papers by this authorE. Hodak, E. Hodak Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, IsraelSearch for more papers by this authorE. Avitan-Hersh, E. Avitan-Hersh Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Division of Dermatology, Rambam Health Care Campus, Haifa, IsraelSearch for more papers by this authorM. Ziv, M. Ziv Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Division of Dermatology, Emek Medical Center, Afula, IsraelSearch for more papers by this authorR.P. Dodiuk-Gad, R.P. Dodiuk-Gad Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Division of Dermatology, Emek Medical Center, Afula, Israel Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this author G. Feraru, Corresponding Author G. Feraru [email protected] orcid.org/0000-0003-4894-197X Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Division of Dermatology, Emek Medical Center, Afula, IsraelCorrespondence: G. Feraru. E-mail: [email protected]Search for more papers by this authorM.J. Nevet, M.J. Nevet Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Division of Dermatology, Rambam Health Care Campus, Haifa, IsraelSearch for more papers by this authorL. Samuelov, L. Samuelov orcid.org/0000-0001-5387-5490 Division of Dermatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, IsraelSearch for more papers by this authorE. Hodak, E. Hodak Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, IsraelSearch for more papers by this authorE. Avitan-Hersh, E. Avitan-Hersh Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Division of Dermatology, Rambam Health Care Campus, Haifa, IsraelSearch for more papers by this authorM. Ziv, M. Ziv Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Division of Dermatology, Emek Medical Center, Afula, IsraelSearch for more papers by this authorR.P. Dodiuk-Gad, R.P. Dodiuk-Gad Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Division of Dermatology, Emek Medical Center, Afula, Israel Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this author First published: 09 June 2022 https://doi.org/10.1111/jdv.18311Citations: 9Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Guttman-Yassky E, Teixeira HD, Simpson EL et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151–2168. 2Reich K, Teixeira HD, de Bruin-Weller M et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169–2181. 3Licata G, Gambardella A, Tancredi V et al. Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol 2020; 101: 590–598. 4Blauvelt A,Teixeira HD,Simpson EL et al. Efficacy and safety of Upadacitinib vs Dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021; 157: 1047–1055. Citing Literature Volume36, Issue10October 2022Pages e832-e833 ReferencesRelatedInformation